MNCs Step Up Competition For China Tumor Drug Market
This article was originally published in PharmAsia News
At the recent annual meeting of the American Society for Clinical Oncology, Bayer HealthCare released the Asia Pacific clinical trial results of its new drug Nexavar (sorafenib). This tumor drug represents the company's first to have its R&D conducted specifically for populations in China and Asia Pacific. Bayer officials say that due to China's huge potential in the tumor drug market, future product trials will consider Chinese patients and, if required, exclusive clinical tests will be carried out. Tumor drugs make up the fastest-growing segment within China's pharmaceutical market, spurring global drug giants to bring their latest offerings into the country. Nexavar was introduced to China only three months after it gained FDA approval in 2006. (Click here for more - Chinese Language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?